REGN catalyst calendar

REGENERON PHARMACEUTICALS, INC.

Upcoming catalysts
77
Cash runway
Cash generating
Cash & investments
$7995M
Phase 3 programs
57

REGENERON PHARMACEUTICALS, INC. is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.

The next scheduled catalyst is A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma on November 2, 2026. There are 77 upcoming events on record.

REGENERON PHARMACEUTICALS, INC. generates cash from operations, so a burn-based runway figure does not apply.

Across 201 concluded trials, 81% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
November 2, 2026 A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Anti-PD1 Alone in Adult Participants With Resectable Stage 3 or 4 Melanoma Trial Milestone Phase 2
November 13, 2026 A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers Trial Milestone Phase 1/Phase 2
November 13, 2026 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity in the US Trial Milestone Phase 2
December 3, 2026 A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body Trial Milestone Phase 2
December 4, 2026 A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults Trial Milestone Phase 1
December 13, 2026 est. Next quarterly earnings (projected) Earnings —
December 29, 2026 A Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia Trial Milestone Phase 2
February 9, 2027 Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation Trial Milestone Phase 2
February 20, 2027 REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults Trial Milestone Phase 3
February 22, 2027 Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity Trial Milestone Phase 1
March 22, 2027 A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) Trial Milestone Phase 3
April 2, 2027 Study of 3 Monoclonal Antibodies (REGN9933, REGN7508, and REGN9533) in Adult Participants With End-Stage Kidney Disease on Hemodialysis Trial Milestone Phase 1
April 24, 2027 Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma Trial Milestone Phase 4
May 15, 2027 A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH) Trial Milestone Phase 1/Phase 2
May 20, 2027 A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 2
July 6, 2027 A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer Trial Milestone Phase 1/Phase 2
August 10, 2027 A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Trial Milestone Phase 1/Phase 2
August 31, 2027 Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy Trial Milestone Phase 1
September 28, 2027 A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 2/Phase 3
September 30, 2027 Safety and Pharmacokinetics of Cemiplimab Anti-programmed Death-ligand 1 (Anti-PD-1) and Other Agents in Japanese Adult Patients With Advanced Malignancies Trial Milestone Phase 1
October 11, 2027 Adult Outpatient Linvoseltamab With Tocilizumab Prophylaxis to Mitigate the Risk of Cytokine Release Syndrome (CRS) Trial Milestone Phase 4
November 22, 2027 A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA) Trial Milestone Phase 1/Phase 2
January 7, 2028 Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma Trial Milestone Phase 3
January 21, 2028 Study of Olatorepatide in Adult Participants Living With Overweight or Obesity Without Diabetes Trial Milestone Phase 2
January 26, 2028 A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) Trial Milestone Phase 2
January 28, 2028 A Study to Investigate Mibavademab in Adult Women With Functional Hypothalamic Amenorrhea Trial Milestone Phase 2
February 7, 2028 A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma Trial Milestone Phase 3
February 27, 2028 Study of REGN13335 in Adult Participants With Pulmonary Arterial Hypertension (PAH) Trial Milestone Phase 2
March 25, 2028 A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments Trial Milestone Phase 1
April 27, 2028 A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition Trial Milestone Phase 2
May 19, 2028 Efficacy and Safety of Mibavademab in Adult and Pediatric Patients With Generalized Lipodystrophy Trial Milestone Phase 3
June 4, 2028 A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Trial Milestone Phase 2
June 19, 2028 A Study of Dupilumab in Small Children With an Allergic Condition of the Esophagus (Food Pipe): Eosinophilic Esophagitis Trial Milestone Phase 3
June 23, 2028 First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis Trial Milestone Phase 1
June 30, 2028 Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer Trial Milestone Phase 2
July 30, 2028 This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization Trial Milestone Phase 4
July 31, 2028 A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy Trial Milestone Phase 3
August 20, 2028 A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis) Trial Milestone Phase 1/Phase 2
October 10, 2028 A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemdisiran Combination Therapy is and How Well it Works Trial Milestone Phase 3
October 13, 2028 Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney Disease Trial Milestone Phase 2
November 8, 2028 A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab Trial Milestone Phase 1/Phase 2
February 26, 2029 A Study of DB-OTO, an Adeno-Associated Virus (AAV) Based Gene Therapy, in Children/Infants, Adolescents and Adults With Hearing Loss Due to Otoferlin Mutations Trial Milestone Phase 1/Phase 2
March 3, 2029 Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Trial Milestone Phase 3
March 28, 2029 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable Trial Milestone Phase 3
May 21, 2029 A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM) Trial Milestone Phase 3
May 31, 2029 A Study to Evaluate the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Adult and Pediatric Participants With Allergic Conjunctivitis Due to Cat Allergy Trial Milestone Phase 3
June 7, 2029 First-in-Human Study of ALN-SNCA in Adult Participants With Early Parkinson's Disease (PD) Trial Milestone Phase 1
June 25, 2029 Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) Trial Milestone Phase 3
July 29, 2029 A Trial to Learn if Odronextamab Combined With Chemotherapy is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Chemotherapy for Adult Participants With Follicular Lymphoma Trial Milestone Phase 3
August 18, 2029 Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease Trial Milestone Phase 3
September 10, 2029 Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis Trial Milestone Phase 1
September 11, 2029 Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation Trial Milestone Phase 3
October 10, 2029 A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment Trial Milestone Phase 2
November 29, 2029 A First-in-Human Safety and Efficacy Study of ALN-CFB, a Small Interfering RNA (siRNA) Targeting Complement Factor B, in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhibitor Trial Milestone Phase 1/Phase 2
January 16, 2030 A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer Trial Milestone Phase 2/Phase 3
January 18, 2030 A Study to Evaluate How Pozelimab + Cemdisiran Combination Therapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Whose Current Treatment is Not Working Efficiently Trial Milestone Phase 3
January 28, 2030 Thyroid-Stimulating Hormone Receptor (TSHR) Blockade With REGN24493 in Adult Participants With Graves' Disease (GD) Trial Milestone Phase 1
February 2, 2030 A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread Trial Milestone Phase 1
February 3, 2030 A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body Trial Milestone Phase 1/Phase 2
February 12, 2030 A Study to Test the Safety of Pozelimab in Pediatric Participants 1 to 5 Years of Age With a Rare Disease Called CHAPLE (Complement Hyperactivation, Angiopathic Thrombosis, Protein-losing Enteropathy) Disease Trial Milestone Phase 4
March 15, 2030 A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD Trial Milestone Phase 2
March 28, 2030 A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With REGN5678 for Adult Participants With Advanced Prostate Cancer Trial Milestone Phase 1/Phase 2
May 3, 2030 Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma Trial Milestone Phase 3
May 27, 2030 A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers Trial Milestone Phase 1
June 10, 2030 A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC) Trial Milestone Phase 2
November 13, 2030 A Study Comparing Cemiplimab-based Treatments for Adult Participants With Locally Advanced Basal Cell Skin Cancer (laBCC) Trial Milestone Phase 2
March 10, 2031 Safety and Efficacy Study in Adults With Advanced Solid Tumors Receiving REGN13089-M404-M2980, an Antibody-drug Conjugate That Targets MET Protein on Tumors Trial Milestone Phase 1/Phase 2
April 30, 2031 A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma Trial Milestone Phase 3
July 28, 2031 REGN21353 Alone or in Combination With Nezastomig for Metastatic Castration-Resistant Prostate Cancer in Adult Participants Trial Milestone Phase 1/Phase 2
May 18, 2032 A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma Trial Milestone Phase 2
August 27, 2032 A Safety and Efficacy Study of Combined Fianlimab + Cemiplimab in Children and Young Adults With Recurrent or Progressive High-Grade Glioma or Posterior Fossa-A Ependymoma Trial Milestone Phase 1/Phase 2
January 25, 2033 A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Adult Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma Trial Milestone Phase 2
March 30, 2033 Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
July 27, 2033 A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Trial Milestone Phase 3
November 11, 2033 A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myeloma Trial Milestone Phase 1/Phase 2
August 14, 2034 A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia B Trial Milestone Phase 1/Phase 2
November 2, 2035 A Window of Opportunity Trial to Learn if Linvoseltamab is Safe and Well Tolerated, and How Well it Works in Adult Participants With Recently Diagnosed Multiple Myeloma Who Have Not Already Received Treatment Trial Milestone Phase 1/Phase 2

Track REGN alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open REGN in the tracker

Recent history

DateEventTypePhase
October 12, 2026 A Study to Evaluate How Safe Pozelimab + Cemdisiran Combination Therapy is and How Well it Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have Not Recently Received or Have Not Received Complement Inhibitor Treatment Trial Milestone Phase 3
October 7, 2026 Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD) Trial Milestone Phase 3
October 6, 2026 Quarterly results filed (8-K) Earnings —
September 30, 2026 8-K filed: Leadership change Corporate —
August 24, 2026 A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery Trial Milestone Phase 2
July 30, 2026 Quarterly results filed (8-K) Earnings —
July 30, 2026 Phase 1 Safety and Tolerability Study of ALN-F1202 in Healthy Adults Trial Milestone Phase 1
July 27, 2026 A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery Trial Milestone Phase 3
July 9, 2026 A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD) Trial Milestone Phase 3
July 6, 2026 Quarterly results filed (8-K) Earnings —
June 17, 2026 A Study to Assess the Anti-Tumor Activity and Safety of Odronextamab in Adult Patients With B-cell Non-Hodgkin Lymphoma Who Have Been Previously Treated With Other Cancer Therapies Trial Milestone Phase 2
June 16, 2026 A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation Trial Milestone Phase 2
May 6, 2026 Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS) Trial Milestone Phase 2
May 2, 2026 Study of Bet v1 Antibodies Effect on Eye Allergy Symptoms in Adolescents and Adults With Birch Pollen Allergy Trial Milestone Phase 3
April 29, 2026 Quarterly results filed (8-K) Earnings —
April 29, 2026 A Study to Learn How Safe and Tolerable Odronextamab and Cemiplimab Are in Adult Patients With B-cell Malignancies Trial Milestone Phase 1
April 8, 2026 Quarterly results filed (8-K) Earnings —
March 27, 2026 A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC) Trial Milestone Phase 2
February 25, 2026 ALN-APOC3 in Adult Participants With Dyslipidemia Trial Milestone Phase 1
February 23, 2026 A Study to Learn How Well Dupilumab Works in Adult and Adolescent Participants With Eosinophilic Gastritis With or Without Eosinophilic Duodenitis and the Side Effects it May Have Trial Milestone Phase 2
January 30, 2026 Quarterly results filed (8-K) Earnings —
January 29, 2026 Phase 1 Safety and Tolerability Study of REGN9533 in Healthy Adults Trial Milestone Phase 1
January 12, 2026 Quarterly results filed (8-K) Earnings —
October 28, 2025 Quarterly results filed (8-K) Earnings —
October 15, 2025 Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Trial Milestone Phase 1
October 6, 2025 Quarterly results filed (8-K) Earnings —
September 19, 2025 A Study of bbT369 in Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma (NHL) Trial Milestone Phase 1
August 26, 2025 A Phase 3b, Single-Arm Study of Aflibercept 8 mg Dosed Every 4 Weeks in Adult Participants With Neovascular Age-Related Macular Degeneration (nAMD) or Diabetic Macular Edema (DME) Trial Milestone Phase 3
August 21, 2025 Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies Trial Milestone Phase 1
August 1, 2025 Quarterly results filed (8-K) Earnings —

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.